PanGenX
  • Products
    • For Patients
    • For Pharma
  • Buzz
  • About Us
    • Leadership Team
    • Advisors
    • Careers
    • Contact Us

About Us

Our team consists of healthcare and IT industry leaders who believe that technology can unleash the power of pharmacogenomics to drive the future of healthcare.

Overview


  • Who we are
  • PanGenX was founded in 2010 with the belief that current treatment outcomes can be improved through effective use of clinical genetic data. We have created a deep collaboration between geneticists and computer scientists. This unique combination has led to the creation of scientifically based, technology driven, decision-making applications to improve the lives of millions of patients suffering worldwide.  Our passion, combined with tenacious efforts to challenge status quo drives our team to bring personalized medicine to the forefront of healthcare.

  • What we do
  • Our mission is to advance clinical practice and treatment approaches by integrating genetic variations related to drug response with patient outcomes. We optimize therapeutic care and decision-making by providing pharmaceutical companies, healthcare providers, and payers with tools to conduct analyses and make more informed decisions through the intelligent use of pharmacogenomics, population genetics, and clinical outcomes data. Ultimately, by informed selection of medicines, patients will endure less side effects and achieve treatment benefits for debilitating, progressive diseases.

     

Leadership

Management Team


  • Daniel A. Poscover, MBA, President and Chief Executive Officer

  • Paul B. Trevithick, Chief Technology Officer

  • David Neafus, Chief Financial Officer

  • Thomas Vasicek, Ph.D., Vice President of Clinical Genetics

  • Seema Pandya, MBA, Vice President of Strategic Marketing

  • Irina I. Agoulnik, Ph.D., Senior Director of Operations

  • Advisors

 

PanGenX

Our mission is to advance clinical practice and treatment approaches by integrating genetic variations related to drug response with patient outcomes. Ultimately, by informed selection of medicines, patients will endure less side effects and achieve treatment benefits for debilitating, progressive diseases.

Learn More

  • Leadership Team
  • For Patients
  • For Pharma
  • Buzz
  • Careers
  • Contact Us

What’s New

  • PanGenX to present at Personalized Medicine World Conference

    24 Jan, 2013
  • The healthcare analytics market is seeing double-digit growth

    08 Jan, 2013
  • Fred Frank Joins as Special Advisor to the PanGenX Board

    16 Feb, 2012

© Copyright 2013 PanGenX. All Rights Reserved.